Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Daiichi Closing Indian Site As Global Restructuring Continues

Executive Summary

Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.

Advertisement

Related Content

Daiichi Seeks To Stall Singh Asset Sales In Ranbaxy Compensation Battle
Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals
Daiichi Sankyo Shutting UK Site As Global Cost Drive Continues
U3 Shut Down As Daiichi Sankyo Streamlines R&D
Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry
Sandoz shutters formulations R&D unit, Indian generic plans intact

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register